VITL

Vital Farms (VITL) is expected to report a quarterly loss of $0.14 per share with revenues declining 7.2% year-over-year for Q3 2026. Despite a positive Earnings ESP of +4.88%, the stock's Zacks Rank #4 rating makes it difficult to predict an earnings beat. The company has only beaten consensus estimates once in the last four quarters, suggesting weak earnings surprise prospects ahead of the November 3 release.

Vital Farms stock declined 2.08% to $8.95, underperforming the broader market gains. The company faces headwinds with projected Q3 EPS of -$0.14 (down 138.89% YoY) and revenue expected at $184.6 million (down 7.21% YoY). Analyst estimates have been revised downward by 10.35% in the past month, resulting in a Zacks Rank #4 (Sell) rating.

Vital Farms (VITL) has attracted significant investor attention but faces headwinds with a Zacks Rank #4 (Sell) rating. The stock has declined 6.7% over the past month, underperforming the S&P 500.

The company is expected to post losses for the current quarter and fiscal year, with negative earnings estimate revisions of -10.4% over the last 30 days. However, consensus estimates suggest a return to profitability next fiscal year with earnings of $0.11 per share.

Vital Farms stock declined 2.86% to $8.16, underperforming the broader market which gained 0.41%. The company's shares have fallen 29.94% over the past month, significantly lagging the Consumer Staples sector.

Analysts expect negative earnings of -$0.14 per share and a 7.21% revenue decline for the upcoming quarter, with full-year projections showing -$0.53 EPS. The stock holds a Zacks Rank of #4 (Sell), and the Food - Miscellaneous industry ranks in the bottom 18% of all industries.

Vital Farms (VITL) declined 1.37% to $9.34, underperforming the S&P 500's 0.02% loss. The stock has fallen 5.58% over the past month while the broader market gained 2.05%.

Upcoming earnings are expected to show an EPS of -$0.13 (down 136.11% year-over-year) and revenue of $190.5 million (down 4.24%), with annual projections showing -$0.48 EPS and $777.9 million revenue. VITL holds a Zacks Rank of #3 (Hold) with no recent estimate changes.

Vital Farms (VITL) closed at $9.47, up 1.5% on the day but down 4.21% over the past month. The company faces challenging earnings expectations with projected EPS of -$0.13 (down 136% YoY) and quarterly revenue of $190.5 million (down 4.24% YoY). The stock holds a Zacks Rank #3 (Hold) rating, while its industry ranks in the bottom 18% of all sectors.

Vital Farms (VITL) has been trending on Zacks.com with shares down 6.6% over the past month. The company is expected to report a loss of $0.13 per share for the current quarter and -$0.48 for the fiscal year, though earnings are projected to recover to $0.28 per share next fiscal year.

Revenue growth is modest at 2.4% for the current year and 5.7% for the next year. The stock has been assigned a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Vital Farms (VITL) closed at $9.42, up 1.84% for the day but down 6.75% over the past month. The company is expected to report negative EPS of -$0.13 and revenue of $190.5 million (down 4.24% YoY).

For the full year, earnings are projected at -$0.48 per share with revenue of $777.9 million. The stock holds a Zacks Rank #3 (Hold) rating, while its industry ranks in the bottom 15% of all sectors.

e.l.f. Beauty is expected to report Q2 fiscal 2027 revenues of $470.6 million, up 36.8% year-over-year, driven by product launches, strategic pricing, and international expansion including Rhode's European launch. However, EPS is projected to decline 10.3% due to increased marketing investments and margin pressures from retail distribution shifts. The company's Earnings ESP of -1.64% suggests limited likelihood of beating consensus estimates.

Anthropic has filed as a Public Benefit Corporation (PBC), a legal status that requires balancing shareholder interests with public benefit and stakeholder concerns. As a PBC focused on AI safety, Anthropic must consider responsible development of AI technology. While PBC status typically has minimal impact on investors, it may provide Anthropic a reputational advantage in the controversial AI space and demonstrates commitment to safety over pure profit maximization.